IDH1 and central nervous system cancer: Additionally, Kadiyala et al. demonstrated that combinatorial therapy involving αPD-L1 blockade with an IDH1-R132H inhibitor, ionizing radiation, and temozolomide significantly extended median survival in mIDH1 glioma-bearing murine models [88].